Strota/ Newsroom/ 2026-07-10

AUROPHARMA (Aurobindo Pharma Ltd.): Acquisition / M&A

Strota Newsroom · session of 2026-07-10 · 10 Jul 13:09 · AUROPHARMA stock page →

Aurobindo Pharma Limited has informed the Exchange about incorporation of a new wholly owned stepdown subsidiary in Indo… Historically, acquisition / m&a events have moved AUROPHARMA-type stocks in the bullish direction 48.9% of the next sessions (n=141).

Aurobindo Pharma has informed the Exchange about the incorporation of a new wholly owned stepdown subsidiary in Indonesia, according to an NSE filing dated 10 July. The company did not disclose transaction terms or intended operations for the unit. This follows the completion of its Lannett acquisition by Aurobindo Pharma USA Inc., which the company reported to the Exchange on 30 June, 1 July and 2 July, and which received US FTC clearance earlier in the month.

Events like this—Acquisition / M&A announcements—have historically produced a 48.9% win rate across 141 comparable instances, with a net edge of 0.213%, according to Strota's base rate data. These figures describe the track record of similar event types, not a forecast for this specific stock.

The stock closed at ₹1,587.4 on 9 July, down 1.37% from the previous session, while the Nifty rose 0.91%. Aurobindo Pharma trades 3.02% below its 52-week high of ₹1,636.8 and 56.22% above its 52-week low of ₹1,016.1. It sits above both its 50-day and 200-day moving averages, with a 14-day RSI of 61.2. Relative volume at 0.52 indicates below-average turnover. The company commands a market capitalisation of ₹89,972 crore, with a price-to-earnings ratio of 25.94 and return on equity of 9.9%.

The filing confirms the subsidiary incorporation and its wholly owned structure. It does not specify capital deployed, revenue contribution timelines, or regulatory approvals required in Indonesia. The base rate offers historical context for how markets have processed similar announcements elsewhere; it does not establish how this specific expansion will affect Aurobindo Pharma's operations or valuation.

The catalyst

Aurobindo Pharma Limited has informed the Exchange about incorporation of a new wholly owned stepdown subsidiary in Indonesia. (filing · NSE)

What the data shows after this event

Across Strota's backtest of past filings, Acquisition / M&A shows no reliable next-session edge — the move went bullish in about 48.9% of next sessions (net 0.213% after drift and cost, n=141). A base rate, not a forecast for this stock.

AUROPHARMA right now

trading -1.37% on the day; P/E 25.94; RSI 61.2. Full AUROPHARMA analysis →

Sources

Aurobindo Pharma Limited has informed the Exchange about incorporation of a new wholly owned stepdown subsidiary in Indonesia. — NSE
Aurobindo Pharma (NSEI:AUROPHARMA) Stock Sees Fair Value Lift On Stronger Growth Assumptions — Simply Wall St.
Aurobindo Pharma shares up 25% in 2026: Nuvama says 'Buy', ups target price; here's why — Business Today
Aurobindo Pharma shares in focus as US FTC clears $250 million Lannett acquisition — Business Today
Aurobindo Pharma Shares Rise After US Regulatory Nod For Lannett Purchase — NDTV Profit

Keep digging

AUROPHARMA — full smart-money page: F&O positioning, deals, insider filings and option chain in one place.
Today's screens: every stock matching the same setups (buildups, breakouts, volume shockers).
Newsroom: the other stocks in play this session.

How this article was made: Strota assembled the exchange data above (prices, F&O open interest, bulk/block deals, SEBI PIT filings, indicator readings and public headlines) and an AI model wrote the narrative strictly from that evidence — it is not permitted to add outside facts or numbers. Every figure comes from the underlying exchange/public data.